TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE: THE CHINA SALT SUBSTITUTE AND STROKE STUDY (SSaSS)
Brief Summary: The study is a large scale cluster randomised trial to evaluate the effects of sodium reduction based upon the use of salt substitute on the risk of stroke defined as the occurrence of stroke and stroke deaths. The corresponding null hypothesis that will be tested is that sodium reduction will have no effect upon stroke risk. The secondary objectives are to determine effects of sodium reduction on major vascular events and total mortality.


Options:
A: Arm Label: Sodium Reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Sodium Reduction | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sodium Reduction; Assigned to Arm(s): Sodium Reduction
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dietary sodium reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary sodium reduction | Intervention Type: BEHAVIORAL; Name: Dietary sodium reduction; Assigned to Arm(s): Dietary sodium reduction
C: Arm Label: intensive sodium management; Type: EXPERIMENTAL; Interventions: Other: intensive sodium management | Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intensive sodium management; Assigned to Arm(s): intensive sodium management
D: Arm Label: Sequence: ABBA A=usual care, B=self-care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BAAB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence AABB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BBAA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Intervention Type: BEHAVIORAL; Name: Self-care management program; Assigned to Arm(s): Sequence AABB, Sequence BAAB, Sequence BBAA, Sequence: ABBA A=usual care, B=self-care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease
Brief Summary: This study will evaluate the safety and efficacy of combination treatment with grazoprevir (MK-5172) + elbasvir (MK-8742) for cirrhotic and non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV) infection and chronic kidney disease (CKD). The primary study hypothesis is that the proportion of HCV GT1-infected CKD participants within the Immediate Treatment and Intensive Pharmacokinetics (PK) groups achieving a sustained viral response 12 weeks after the end of all study treatment (SVR12) will be \>45%.


Options:
A: Arm Label: Immediate Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: Deferred Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Grazoprevir, Drug: Placebo to Elbasvir | Arm Label: Intensive PK; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Placebo to Grazoprevir; Assigned to Arm(s): Deferred Treatment | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): Deferred Treatment
B: Arm Label: ABT-493/ABT-530; Type: EXPERIMENTAL; Interventions: Drug: ABT-493/ABT-530 | Intervention Type: DRUG; Name: ABT-493/ABT-530; Assigned to Arm(s): ABT-493/ABT-530
C: Arm Label: hepatitis C and/or B; Type: N/A; Interventions: N/A
D: Arm Label: Peginterferon alfa-2a and ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a and ribavirin | Arm Label: Peginterferon alfa-2a; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a | Intervention Type: DRUG; Name: Peginterferon alfa-2a and ribavirin; Assigned to Arm(s): Peginterferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): Peginterferon alfa-2a

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study
Brief Summary: The Southeastern Kidney Transplant Coalition is an academic-community collaboration between partners in the kidney disease community who share the common goal of eliminating health disparities in access to kidney transplantation among African American End Stage Renal Disease living in Georgia, North Carolina, and South Carolina. Volunteer members of this community-based coalition include patients with kidney disease, dialysis facility staff and providers, transplant centers, quality improvement organizations, and patient advocacy organizations. The burden of kidney disease is highest in the Southeast, and yet the rate of kidney transplantation is the lowest in the nation. Further, the investigators research suggests that racial disparities in access to kidney transplantation are concentrated in the Southeast, where African Americans are less likely to access each step in the transplant process. The long-term goal of the investigators Coalition is to use community- based participatory research approaches to develop, test, and disseminate sustainable, community interventions improve access to transplant for African American patients with kidney disease. The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) community study proposes to use community-based participatory research methods to develop a multilevel intervention to reduce racial disparities in access to kidney transplantation. The long-term impact of this application will be to reduce racial disparities in the kidney disease community.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): B
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Interventions for Dialysis Facilities | Intervention Type: BEHAVIORAL; Name: Behavioral Interventions for Dialysis Facilities; Assigned to Arm(s): Behavioral Intervention
C: Arm Label: HED-Start Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: HED-Start | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HED-Start; Assigned to Arm(s): HED-Start Intervention arm
D: Arm Label: Integrated Chronic Kidney Disease care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Chronic Kidney Disease care | Arm Label: Conventional CKD care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional CKD care | Intervention Type: BEHAVIORAL; Name: Integrated Chronic Kidney Disease care; Assigned to Arm(s): Integrated Chronic Kidney Disease care | Intervention Type: BEHAVIORAL; Name: Conventional CKD care; Assigned to Arm(s): Conventional CKD care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)
Brief Summary: The objective of this study is to develop and test an emergency department (ED)-based intervention which uses text messages to facilitate contraception initiation.


Options:
A: Arm Label: Text Messaging Intervention; Type: EXPERIMENTAL; Interventions: Other: Text Messaging Intervention | Arm Label: Standard Referral; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Referral | Intervention Type: OTHER; Name: Text Messaging Intervention; Assigned to Arm(s): Text Messaging Intervention | Intervention Type: OTHER; Name: Standard Referral; Assigned to Arm(s): Standard Referral
B: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone reminder | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mobile phone reminder | Intervention Type: BEHAVIORAL; Name: Mobile phone reminder; Assigned to Arm(s): Control, Intervention
D: Intervention Type: BEHAVIORAL; Name: Pulse; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)
Brief Summary: The objective of this study is to develop and test an emergency department (ED)-based intervention which uses text messages to facilitate contraception initiation.


Options:
A: Arm Label: Text Messaging Intervention; Type: EXPERIMENTAL; Interventions: Other: Text Messaging Intervention | Arm Label: Standard Referral; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Referral | Intervention Type: OTHER; Name: Text Messaging Intervention; Assigned to Arm(s): Text Messaging Intervention | Intervention Type: OTHER; Name: Standard Referral; Assigned to Arm(s): Standard Referral
B: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS reminder; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminder | Arm Label: SMS reminder + Unconditional Incentive; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminder, Behavioral: Unconditional Incentive | Intervention Type: BEHAVIORAL; Name: SMS reminder; Assigned to Arm(s): SMS reminder, SMS reminder + Unconditional Incentive | Intervention Type: BEHAVIORAL; Name: Unconditional Incentive; Assigned to Arm(s): SMS reminder + Unconditional Incentive
D: Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care Treatment | Arm Label: Mobile Health Messaging Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Health Messaging application, Other: Standard of Care Treatment | Arm Label: Focus Group Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile Health Messaging application; Assigned to Arm(s): Mobile Health Messaging Arm | Intervention Type: OTHER; Name: Standard of Care Treatment; Assigned to Arm(s): Control Arm, Mobile Health Messaging Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)
Brief Summary: The objective of this study is to develop and test an emergency department (ED)-based intervention which uses text messages to facilitate contraception initiation.


Options:
A: Arm Label: SMS Reminder; Type: EXPERIMENTAL; Interventions: Other: SMS Reminder | Arm Label: Interactive Reminder; Type: EXPERIMENTAL; Interventions: Other: Interactive Reminder | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SMS Reminder; Assigned to Arm(s): SMS Reminder | Intervention Type: OTHER; Name: Interactive Reminder; Assigned to Arm(s): Interactive Reminder
B: Arm Label: Crowdsourced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Crowdsourced materials | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Crowdsourced materials; Assigned to Arm(s): Crowdsourced intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Text Messaging Intervention; Type: EXPERIMENTAL; Interventions: Other: Text Messaging Intervention | Arm Label: Standard Referral; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Referral | Intervention Type: OTHER; Name: Text Messaging Intervention; Assigned to Arm(s): Text Messaging Intervention | Intervention Type: OTHER; Name: Standard Referral; Assigned to Arm(s): Standard Referral
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders | Intervention Type: BEHAVIORAL; Name: Reminders; Assigned to Arm(s): Reminders

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.


Options:
A: Arm Label: BCX4161 300 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161, Drug: Placebo | Arm Label: BCX4161 500 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161 | Arm Label: Placebo three times daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 300 mg three times daily, BCX4161 500 mg three times daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BCX4161 300 mg three times daily, Placebo three times daily
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CSL312 (low); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med/high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Intervention Type: BIOLOGICAL; Name: Factor XIIa antagonist monoclonal antibody; Assigned to Arm(s): CSL312 (high), CSL312 (low), CSL312 (med), CSL312 (med/high) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CSL312; Type: EXPERIMENTAL; Interventions: Biological: CSL312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: CSL312; Assigned to Arm(s): CSL312 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: DX-2930, Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DX-2930; Assigned to Arm(s): DX-2930, Cohort 1, DX-2930, Cohort 2, DX-2930, Cohort 3, DX-2930, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Decrease in Cholesterol Levels Induced by a Statin on Sperm Quality
Brief Summary: Recently, concerns about the effect of atorvastatin intake on men fertility have been raised. However, this statin has never been investigated regarding its influence on male fertility, notably sperm quality.

The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.


Options:
A: Arm Label: atovastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): atovastatin
B: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
D: Arm Label: atorvastatin matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: atorvastatin matching placebo | Arm Label: atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): atorvastatin | Intervention Type: DRUG; Name: atorvastatin matching placebo; Assigned to Arm(s): atorvastatin matching placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nitrous Oxide for Pain Management of First Trimester Surgical Abortion
Brief Summary: The purpose of this research is to study the effect of nitrous oxide on pain felt by women having a surgical termination at less than 11 weeks compared to pain felt by women receiving oral pain medications.


Options:
A: Arm Label: Transcutaneous electrical nerve stimulation (TENS); Type: EXPERIMENTAL; Interventions: Device: Transcutaneous electrical nerve stimulation (TENS), Other: SHAM: Moderate IV Sedation | Arm Label: Moderate IV Sedation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moderate IV Sedation, Other: SHAM: Transcutaneous electrical nerve stimulation (TENS) | Intervention Type: DEVICE; Name: Transcutaneous electrical nerve stimulation (TENS); Assigned to Arm(s): Transcutaneous electrical nerve stimulation (TENS) | Intervention Type: DRUG; Name: Moderate IV Sedation; Assigned to Arm(s): Moderate IV Sedation | Intervention Type: OTHER; Name: SHAM: Transcutaneous electrical nerve stimulation (TENS); Assigned to Arm(s): Moderate IV Sedation | Intervention Type: OTHER; Name: SHAM: Moderate IV Sedation; Assigned to Arm(s): Transcutaneous electrical nerve stimulation (TENS)
B: Arm Label: Nitrous oxide administration; Type: EXPERIMENTAL; Interventions: Other: Nitrous oxide administration | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nitrous oxide administration; Assigned to Arm(s): Nitrous oxide administration
C: Arm Label: No Paracervical Block for Pain Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Paracervical Block | Arm Label: Paracervical Block for Pain Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paracervical Block | Intervention Type: PROCEDURE; Name: Paracervical Block; Assigned to Arm(s): Paracervical Block for Pain Control | Intervention Type: PROCEDURE; Name: Sham Paracervical Block; Assigned to Arm(s): No Paracervical Block for Pain Control
D: Arm Label: paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: paracetamol | Arm Label: without drug; Type: ACTIVE_COMPARATOR; Interventions: Other: without drug | Arm Label: dexketoprofen trometamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexketoprofen trometamol | Arm Label: two puff xylocain administration on cervical surface; Type: ACTIVE_COMPARATOR; Interventions: Drug: suction curettage | Arm Label: paracervical block with ultracaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: suction curettage | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol | Intervention Type: DRUG; Name: dexketoprofen trometamol; Assigned to Arm(s): dexketoprofen trometamol | Intervention Type: DRUG; Name: suction curettage; Assigned to Arm(s): two puff xylocain administration on cervical surface | Intervention Type: DRUG; Name: suction curettage; Assigned to Arm(s): paracervical block with ultracaine | Intervention Type: OTHER; Name: without drug; Assigned to Arm(s): without drug

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron Both in Combination With Dexamethasone to Prevent Postoperation Nausea and Vomiting in Women
Brief Summary: The purpose of this study is to access the effect of TEAS of P6 in the prevention of PONV in women scheduled for gynecologic laparoscopic surgery with general anesthesia.


Options:
A: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A
B: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Transcutaneous electrical acupoint stimulation, Drug: Dexamethasone | Arm Label: Tropisetron; Type: ACTIVE_COMPARATOR; Interventions: Device: Sham transcutaneous electrical acupoint stimulation, Drug: Tropisetron, Drug: Dexamethasone | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcutaneous electrical acupoint stimulation, Drug: Dexamethasone | Intervention Type: DEVICE; Name: Transcutaneous electrical acupoint stimulation; Assigned to Arm(s): Acustimulation | Intervention Type: DEVICE; Name: Sham transcutaneous electrical acupoint stimulation; Assigned to Arm(s): Control, Tropisetron | Intervention Type: DRUG; Name: Tropisetron; Assigned to Arm(s): Tropisetron | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Acustimulation, Control, Tropisetron
C: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: APD405 | Intervention Type: DRUG; Name: APD405; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: B